Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.

This chapter reviews differences in dermatological treatments and conditions between male and female patients, particularly noting the impacts of sex steroids on various skin processes, but presents no new clinical findings.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This review discusses current knowledge on the biological mechanisms of different types of alopecia but reports no new clinical findings; the authors highlight future research directions, especially regarding epidermal stem cells and immune pathways.

This abstract explains that androgenetic alopecia, a common hair loss disorder influenced by genetics and hormones like dihydrotestosterone, has FDA-approved treatments including minoxidil, finasteride, and photolaser therapy, but its genetic basis and susceptibility to environmental factors remain complex.

This review summarizes recent therapeutic advancements in treating various forms of alopecia, including new applications of oral minoxidil, dutasteride, finasteride, Janus kinase inhibitors, and novel hair transplant techniques, without presenting original research results.

Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.

This thesis review found that invasive methods like PRP and hair transplantation can significantly improve hair quality and density in androgenetic alopecia, though effectiveness and safety vary by technique.

This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

This study established consensus guidelines for diagnosing and managing androgenetic alopecia in Egypt, emphasizing individualized care and emerging therapies based on a survey of Egyptian dermatologists and refinement through expert review.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

The document concludes that ongoing medical therapy is crucial for preventing hair loss, and surgical options can restore hair, with future treatments for hair loss being promising.

This abstract describes the use of lasers in hair transplantation for creating recipient sites and enhancing hair growth but reports no new findings.

This review discusses recent therapeutic advances in treating various types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and hair transplant technologies, but reports no new clinical results.

This review evaluates PRP, microneedling, and LLLT for alopecia and telogen effluvium, reporting improvements of 30-40% but offers no new clinical data.

This review examines how regenerative therapies targeting shared biological pathways can promote healing in musculoskeletal disorders and hair follicle dysfunction, highlighting modalities like platelet-rich plasma and laser therapy while addressing challenges in standardization and measurement.

This review of existing literature reports that photobiomodulation shows high effectiveness and safety in treating dermatological conditions like acne, psoriasis, and alopecia, though standardized clinical trials are needed to further validate its therapeutic benefits.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

In this case study, researchers reported a 37-year-old woman with androgenetic alopecia and chronic telogen effluvium experienced significant hair growth improvement after personalized integrative treatment, including caffeine application, following a four-month protocol incorporating various therapies.

This study found that among patients with Down syndrome, those with alopecia areata may have increased antiperoxidase antibodies, possibly linked to hypothyroidism.

In this study, low-dose BPA was associated with induced prostatic hyperplasia in rats, potentially mediated by COX-2 and L-PGDS through pathways involving cell proliferation and apoptosis.

This study concluded that low energy laser therapy may effectively complement classical treatment for scalp alopecia, leading to faster results, although long-term maintenance still requires ongoing classical therapy.

This article reviews the immunometabolic mechanisms linking polycystic ovary syndrome to infertility and stresses the need for interdisciplinary approaches to treat PCOS-related fertility issues; it reports no new clinical results.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This clinical review evaluates current evidence on various adjunctive therapies for androgenetic alopecia, highlighting modest benefits for some interventions but emphasizing significant gaps and the need for rigorous, high-quality research to guide effective management strategies.

Androgenetic alopecia treatments focus on reducing hair loss by targeting hormones, with new therapies showing promise but needing more research.

In this retrospective case series, researchers observed that a combined treatment protocol of homoeopathy, Xogen therapy, diet, and vitamin supplementation progressively reduced hair fall and improved hair density in five male patients with androgenic alopecia.

Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.

This study examined the factors contributing to gray hair, such as genetics and lifestyle, and found that while graying correlates with some health conditions, it is primarily a physiological process rather than a pathological one.

This review synthesizes data suggesting that managing inflammation and oxidative stress may enhance the effectiveness of PRP therapy for hair regeneration, though standardizing PRP protocols remains challenging.